Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update

SIMPLE SUMMARY: Only 5% of all drug-related targets currently move from preclinical to clinical in cancer, and just some of them achieve patient’s bedside. Among others, intratumor heterogeneity and preclinical cancer model limitations actually represent the main reasons for this failure. Cyclic-AMP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapio, Luigi, Salzillo, Alessia, Ragone, Angela, Illiano, Michela, Spina, Annamaria, Naviglio, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693618/
https://www.ncbi.nlm.nih.gov/pubmed/33126560
http://dx.doi.org/10.3390/cancers12113166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693618/
https://www.ncbi.nlm.nih.gov/pubmed/33126560
http://dx.doi.org/10.3390/cancers12113166

Ejemplares similares